Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVSNYSE / NASDAQHealthcareSmall cap

$9.67-$0.34 (-3.4%)

Last close · Data as of Nov 20, 2026

Market cap
$985.5M
P/E
-64.5x
EV / EBITDA
-22.9x
Revenue
$0.00
ROCE
-69.6%

This period includes a one-day price step on 20 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Corvus Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-5.5%
3M
-32.5%
6M
-20.7%
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 20 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 20 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.34 (-3.4%) from $10.01 to $9.67 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CRVS, bought on each weekday since 2021.

News & filings

What Corvus Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 15.3 million US dollars in fiscal 2025.

Strengths (1)

  • The company carries almost no debt: debt to equity of 0.02.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.
  • This period includes a one-day price step on 20 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.

Read moreShow less

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Sector
Healthcare
Shares outstanding
74.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$985.5M
P/E
-64.5x
P/B
16.1x
EV / EBITDA
-22.9x
52-week high
Hidden
52-week low
Hidden

Profitability

ROE
-25.0%
ROCE
-69.6%
ROIC
-59.0%
ROA
-21.5%

Growth

Revenue
$0.00
Net profit growth, 1Y
-75.5%
Free cash flow
-$33.0M

Solvency

Current ratio
6.21
Debt / Equity
0.02
Debt / Assets
0.01
CFO / Net profit
2.15
Cash / Market cap
0.5%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Corvus Pharmaceuticals, Inc. revenue and net profit by fiscal year
Corvus Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$41.3M
FY2023$0.00-$27.0M
FY2024$0.00-$62.3M
FY2025$0.00-$15.3M

Cash flows

FY2025: -$32.8M from operations, -$33.0M free after investment (dashed).

Corvus Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Corvus Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$27.0M-$27.3M
FY2023-$23.9M-$24.0M
FY2024-$25.4M-$25.4M
FY2025-$32.8M-$33.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$42.9M
Net profit
-$15.3M
Cash from operations
-$32.8M
Free cash flow
-$33.0M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$42.9M-$15.3M-$33.0M-25.0%—-75.5%

Monthly returns

Month-by-month returns of CRVS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$71.1M
Liabilities$9.9M
Equity$61.2M
Paid-in capital$474.4M
Retained earnings-$412.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CRVS highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Corvus Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Corvus Pharmaceuticals, Inc.CRVSthis company$985.5M-64.5x16.1x-25.0%-22.9x
QuidelOrtho CorporationQDEL$1.0B-0.9x0.5x-58.9%-7.7x
EyePoint, Inc.EYPT$1.0B-4.4x3.4x-75.8%-4.1x
Artivion, Inc.AORT$1.0B103.7x2.3x2.2%18.9x
InnovAge Holding Corp.INNV$977.3M-32.2x4.2x-12.9%-102.4x
U.S. Physical Therapy, Inc.USPH$940.1M62.4x2.0x3.2%11.1x
Anteris Technologies Global Corp.AVR$939.4M—48.7x-238.4%—
Olema Pharmaceuticals, Inc.OLMA$932.9M-5.7x1.9x-33.9%-5.0x
Nutex Health Inc.NUTX$929.7M13.1x2.8x21.5%3.8x
Peer median—-0.9x2.5x-23.4%-4.1x

Year-to-date ROI

CRVS since 1 January, against earlier years.

Historical volatility

CRVS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$43.0M
Research and developmentResearch And Development$33.7M
Total expensesTotal Expenses$43.0M
Pretax incomePretax Income-$15.3M

Learn while you research

Academy chapters picked for Corvus Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →